Login
$ALKS
$46.53 -$0.50 (1.06%) Live

Company Executives

Officer Age Joined 2025 pay Source
Richard F. Pops Also a director
Chief Executive Officer and Chairman of the Board
64 Not stated $7,915,081
Blair C. Jackson
President & CEO, Alkermes plc
Title from the Form 4 dated Aug 5, 2026
53 1999 $4,030,905
Joshua Reed
Senior Vice President, Chief Financial Officer
53 2025 $3,797,074
Jackson
President
Not stated Not stated Not reported
David J. Gaffin
EVP, CLO, Alkermes, Inc.
Title from the Form 4 dated Nov 3, 2026
54 2005 $3,470,083
Craig C. Hopkinson
EVP R&D, Chief Medical Officer
Title from the Form 4 dated Sep 1, 2026
58 Not stated $3,617,908
C. Todd Nichols
Senior Vice President, Chief Commercial Officer
57 Not stated $2,790,694
Samuel Joseph Parisi
VP, Finance (Interim PAO)
Title from the Form 4 dated May 29, 2026
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 6, 2026 · updated by the 8-Ks of Aug 3, 2026 and Sep 16, 2026

Directors
10
serving now
Independent
7 of 8
stated in the proxy; 2 not stated
Average tenure
7.1 years
from year joined
CEO also chairs the board
Yes
Richard F. Pops
Director On board Independent Committees Other public boards 2025 pay Source
Richard F. Pops
2011
15 years
Not independent
Financial Operating
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) Paid as CEO
Shane M. Cooke
2018
8 years
Independent
Audit and Risk · Chair
Prothena Corporation plc (Nasdaq: PRTA) $484,751
Richard B. Gaynor
2019
7 years
Independent
Compensation · Chair
Zai Lab Limited (Nasdaq: ZLAB) $474,014
Cato T. Laurencin
2021
5 years
Independent
Financial Operating
MiMedx Group, Inc. (Nasdaq: MDXG) Not stated
Nancy S. Lurker
2024
2 years
Independent
Compensation Nominating and Corporate Governance · Chair
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), Collegium Pharmaceutical, Inc. (Nasdaq: COLL) $476,212
Brian P. McKeon
2020
6 years
Independent
Compensation Financial Operating · Chair Nominating and Corporate Governance
Dentsply Sirona Inc. (Nasdaq: XRAY) $491,333
Nancy L. Snyderman
2016
10 years
Independent
Audit and Risk Financial Operating
None stated $479,135
Christopher I. Wright
2022
4 years
Independent
Audit and Risk Compensation
None stated Not stated
- -
Financial Operating Committee
- -
Anne C. Whitaker Joined Sep 14, 2026
- - - - -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

No related-party transactions disclosed

The proxy filed Apr 6, 2026 states there were none.

Read it in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support